Researchers discovered that levels of GP73 were elevated among patients suffering from non-alcoholic steatohepatitis (NASH), an advanced and potentially progressive form of NAFLD, when compared to simple steatosis patients—suggesting it can assist in differentiating between them as part of disease diagnosis and management [14]. This evidence concerns the gene GOLM1 and metabolic dysfunction-associated steatotic liver disease.